MRZM (Marizyme) Other Financing: $3.34 Mil (TTM As of Sep. 2024)


MRZM Marizyme Inc MRZM
12 GF Score
Price $0.00
View Full Analysis

What is Marizyme Other Financing?

Marizyme MRZM -99.67% 12 Other Financing is $3.34 Mil as of Sep. 2024. GuruFocus rates MRZM with a GF Score™ of 12/100.

Marizyme's Other Financing for the three months ended in Sep. 2024 was $0.00 Mil.

Marizyme's Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 was $3.34 Mil.

Marizyme Other Financing Historical Data

* Premium members only.

The historical data trend for Marizyme's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marizyme Other Financing Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.27

Marizyme Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.84 0.00 0.50 0.00
MRZM
12GF Score
Marizyme Inc MRZM
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marizyme Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $3.34 Mil mean?
Marizyme (MRZM) has a Other Financing of $3.34 Mil as of Sep. 2024. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Marizyme and its competitors.
Is Marizyme's Other Financing too high?
Marizyme's current Other Financing is $3.34 Mil. Overall, Marizyme has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Marizyme's Other Financing compare to CNBX and XSNX?
Marizyme's Other Financing of $3.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Marizyme and its competitors. Marizyme's current Other Financing is $3.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marizyme stock overvalued right now?
Marizyme (MRZM) has a current Other Financing of $3.34 Mil. The current Other Financing is $3.34 Mil. Marizyme's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Marizyme (MRZM), the current Other Financing is $3.34 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marizyme Business Description

Address 555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
12GF Score

Get the complete analysis for MRZM

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price